Edap Tms Sa (EDAP)

$3.1

-0.04

(-1.27%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $3.01
    $3.29
    $3.10
    downward going graph

    2.9%

    Downside

    Day's Volatility :8.51%

    Upside

    5.78%

    downward going graph
  • $2.71
    $8.50
    $3.10
    downward going graph

    12.58%

    Downside

    52 Weeks Volatility :68.12%

    Upside

    63.53%

    downward going graph

Returns

PeriodEdap Tms SaIndex (Russel 2000)
3 Months
-40.95%
0.0%
6 Months
-58.78%
0.0%
1 Year
-50.0%
0.0%
3 Years
-48.33%
-22.3%

Highlights

Market Capitalization
115.0M
Book Value
$1.28
Earnings Per Share (EPS)
-0.59
PEG Ratio
90.47
Wall Street Target Price
11.28
Profit Margin
-31.7%
Operating Margin TTM
-38.93%
Return On Assets TTM
-11.69%
Return On Equity TTM
-35.48%
Revenue TTM
62.0M
Revenue Per Share TTM
1.67
Quarterly Revenue Growth YOY
10.6%
Gross Profit TTM
24.2M
EBITDA
-14.5M
Diluted Eps TTM
-0.59
Quarterly Earnings Growth YOY
-0.62
EPS Estimate Current Year
-0.59
EPS Estimate Next Year
-0.52
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.17

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Edap Tms Sa(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 263.87%

Current $3.10
Target $11.28

Company Financials

FY18Y/Y Change
Revenue
44.6M
↑ 9.61%
Net Income
-384.5K
↓ 50.37%
Net Profit Margin
-0.86%
↑ 1.05%
FY19Y/Y Change
Revenue
49.9M
↑ 14.62%
Net Income
1.7M
↓ 547.34%
Net Profit Margin
3.37%
↑ 4.23%
FY20Y/Y Change
Revenue
50.7M
↓ 7.23%
Net Income
-2.1M
↓ 212.7%
Net Profit Margin
-4.09%
↓ 7.46%
FY21Y/Y Change
Revenue
49.8M
↑ 5.77%
Net Income
791.3K
↓ 141.08%
Net Profit Margin
1.59%
↑ 5.68%
FY22Y/Y Change
Revenue
58.3M
↑ 25.06%
Net Income
-3.1M
↓ 519.0%
Net Profit Margin
-5.32%
↓ 6.91%
FY23Y/Y Change
Revenue
64.6M
↑ 7.4%
Net Income
-22.6M
↑ 607.26%
Net Profit Margin
-35.05%
↓ 29.73%
Q1 FY23Q/Q Change
Revenue
16.8M
↑ 6.24%
Net Income
-5.5M
↓ 31.5%
Net Profit Margin
-32.64%
↑ 17.99%
Q2 FY23Q/Q Change
Revenue
15.5M
↓ 9.16%
Net Income
-5.1M
↓ 8.44%
Net Profit Margin
-32.9%
↓ 0.26%
Q3 FY23Q/Q Change
Revenue
12.5M
↓ 17.8%
Net Income
-4.2M
↓ 16.01%
Net Profit Margin
-33.62%
↓ 0.72%
Q4 FY23Q/Q Change
Revenue
20.8M
↑ 62.82%
Net Income
-5.4M
↑ 24.52%
Net Profit Margin
-25.71%
↑ 7.91%
Q1 FY24Q/Q Change
Revenue
16.3M
↓ 21.53%
Net Income
-5.0M
↓ 6.94%
Net Profit Margin
-30.49%
↓ 4.78%
Q2 FY24Q/Q Change
Revenue
17.1M
↑ 5.84%
Net Income
-6.6M
↑ 34.78%
Net Profit Margin
-38.83%
↓ 8.34%
FY18Y/Y Change
Total Assets
55.4M
↑ 3.93%
Total Liabilities
27.0M
↑ 9.37%
FY19Y/Y Change
Total Assets
59.0M
↑ 8.88%
Total Liabilities
28.6M
↑ 8.13%
FY20Y/Y Change
Total Assets
67.1M
↑ 4.0%
Total Liabilities
35.2M
↑ 12.58%
FY21Y/Y Change
Total Assets
87.3M
↑ 39.92%
Total Liabilities
30.7M
↓ 6.13%
FY22Y/Y Change
Total Assets
107.0M
↑ 30.94%
Total Liabilities
31.2M
↑ 8.53%
FY23Y/Y Change
Total Assets
100.0M
↓ 9.39%
Total Liabilities
37.8M
↑ 17.51%
Q1 FY23Q/Q Change
Total Assets
108.2M
↑ 0.35%
Total Liabilities
31.6M
↓ 12.78%
Q2 FY23Q/Q Change
Total Assets
103.4M
↓ 5.73%
Total Liabilities
34.8M
↑ 8.89%
Q3 FY23Q/Q Change
Total Assets
99.6M
↓ 2.16%
Total Liabilities
35.4M
↑ 3.32%
Q4 FY23Q/Q Change
Total Assets
100.0M
↓ 1.76%
Total Liabilities
37.8M
↑ 4.44%
Q1 FY24Q/Q Change
Total Assets
96.9M
↓ 2.69%
Total Liabilities
39.3M
↑ 4.24%
Q2 FY24Q/Q Change
Total Assets
88.5M
↓ 7.79%
Total Liabilities
37.2M
↓ 4.35%
FY18Y/Y Change
Operating Cash Flow
199.1K
↓ 105.72%
Investing Cash Flow
-1.8M
↓ 22.79%
Financing Cash Flow
1.3M
↓ 58.97%
FY19Y/Y Change
Operating Cash Flow
4.2M
↑ 2071.43%
Investing Cash Flow
-1.7M
↓ 2.36%
Financing Cash Flow
-737.9K
↓ 156.37%
FY20Y/Y Change
Operating Cash Flow
2.4M
↓ 47.97%
Investing Cash Flow
-2.4M
↑ 31.27%
Financing Cash Flow
3.9M
↓ 582.08%
FY21Y/Y Change
Operating Cash Flow
5.0M
↑ 124.84%
Investing Cash Flow
-1.9M
↓ 18.55%
Financing Cash Flow
22.9M
↑ 533.11%
FY22Y/Y Change
Operating Cash Flow
-3.2M
↓ 168.03%
Investing Cash Flow
-2.5M
↑ 45.18%
Financing Cash Flow
23.0M
↑ 7.28%
Q1 FY23Q/Q Change
Operating Cash Flow
-7.1M
↑ 0.0%
Investing Cash Flow
-1.2M
↓ 106.53%
Financing Cash Flow
366.0K
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-6.4M
↓ 11.27%
Investing Cash Flow
-1.2M
↑ 0.0%
Financing Cash Flow
23.9K
↓ 93.57%

Technicals Summary

Sell

Neutral

Buy

Edap Tms Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Edap Tms Sa
Edap Tms Sa
-36.48%
-58.78%
-50.0%
-48.33%
-14.6%
Cardinal Health, Inc.
Cardinal Health, Inc.
12.1%
-1.67%
26.17%
108.06%
138.72%
Cencora Inc
Cencora Inc
-2.54%
-1.12%
31.87%
54.16%
104.7%
Mckesson Corporation
Mckesson Corporation
-18.35%
-4.6%
20.44%
145.35%
250.63%
Henry Schein, Inc.
Henry Schein, Inc.
4.62%
-8.52%
-7.25%
-12.43%
9.9%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Edap Tms Sa
Edap Tms Sa
NA
NA
90.47
-0.59
-0.35
-0.12
NA
1.28
Cardinal Health, Inc.
Cardinal Health, Inc.
32.4
32.4
0.96
7.36
0.0
0.03
0.02
-13.17
Cencora Inc
Cencora Inc
25.65
25.65
1.33
13.61
1.88
0.03
0.01
4.7
Mckesson Corporation
Mckesson Corporation
22.99
22.99
1.46
27.59
0.0
0.04
0.01
-13.53
Henry Schein, Inc.
Henry Schein, Inc.
25.77
25.77
1.54
4.75
0.07
0.04
NA
27.64
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Edap Tms Sa
Edap Tms Sa
Buy
$115.0M
-14.6%
NA
-31.7%
Cardinal Health, Inc.
Cardinal Health, Inc.
Hold
$27.3B
138.72%
32.4
0.38%
Cencora Inc
Cencora Inc
Buy
$46.3B
104.7%
25.65
0.65%
Mckesson Corporation
Mckesson Corporation
Buy
$66.8B
250.63%
22.99
0.94%
Henry Schein, Inc.
Henry Schein, Inc.
Hold
$8.9B
9.9%
25.77
2.82%

Insights on Edap Tms Sa

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 14.99M → 15.87M (in $), with an average increase of 5.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -4.57M → -6.16M (in $), with an average decrease of 34.8% per quarter

  • Vs COR

    In the last 1 year, Cencora Inc has given 31.9% return, outperforming this stock by 81.9%

  • Vs MCK

    In the last 3 years, Mckesson Corporation has given 54.2% return, outperforming this stock by 102.5%

Institutional Holdings

  • Soleus Capital Management, L.P.

    19.66%

  • Morgan Stanley - Brokerage Accounts

    9.09%

  • Rock Springs Capital Management LP

    3.98%

  • Archon Capital Management LLC

    3.06%

  • Federated Hermes Inc

    2.18%

  • Bruce & Co Inc

    1.49%

Company Information

global leader in therapeutic ultrasound and present in the market for more than 30 years, edap tms (nasdaq: edap) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. edap tms is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. by constantly investing in research & development and partnering with internationally renowned medical research institutions, edap tms has developed a strong valuable patent portfolio based on its innovative technologies. with its complete range of robotic hifu devices, edap tms is the most innovative company in minimally-invasive treatment for localized prostate cancer. by combining the latest technologies in imaging and treatment modalities, edap tms just introduced the focal one® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing ablatherm® hifu. as a pioneer and ke

Organization
Edap Tms Sa
Employees
307
CEO
Mr. Marc Oczachowski
Industry
Health Technology

Discover More

FAQs